RGLS - レグルス・セラピュ―ティクス (Regulus Therapeutics Inc.) レグルス・セラピュ―ティクス

 RGLSのチャート


 RGLSの企業情報

symbol RGLS
会社名 Regulus Therapeutics Inc (レグルス・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 レグルス・セラピューティクス(Regulus Therapeutics Inc.)はミクロリボ核酸(RNA)をターゲットとして種々の疾患を治療するためのファーストインクラスの薬剤の発見と開発を中心とするバイオ医薬品会社。ミクロRNAは自然発生的なリボ核酸で、重要な生物学的経路の調節に大切な役割を果たす分子である。同社はミクロRNA製品ラットフォームを使用してアンチmiRと呼ばれる、化学的に修飾された一本鎖オリゴヌクレオチドを開発する。同社はこれらアンチmiRを使用してミクロRNAを調節して、異常細胞を健康状態に返す。平成24年8月、同社は心血管疾患、代謝性疾患と腫瘍のためのミクロRNA治療薬を発見・開発するために、AstraZenecaと戦略的提携を形成した。   レグルス・セラピュ―ティクスは米国のバイオ製薬会社。マイクロRNAを標的とする医薬品の探索と開発に従事。製品は、C型肝炎感染症、心臓血管疾患、線維症、がん、メタボリックなどの治療に用いる。アストラゼネカ、グラクソスミスクライン、サノフィ、バイオジェン・アイデックなどとの戦略的提携を進める。本社はカリフォルニア州サンディエゴ。   Regulus Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in La Jolla, CA.
本社所在地 10614 Science Center Drive San Diego CA 92121 USA
代表者氏名 Stelios Papadopoulos Stelios Papadopoulos
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 858-202-6300
設立年月日 39326
市場名 NASDAQ National Market System
ipoyear 2012年
従業員数
url www.regulusrx.com
nasdaq_url https://www.nasdaq.com/symbol/rgls
adr_tso
EBITDA EBITDA(百万ドル) -55.76000
終値(lastsale) 2.36
時価総額(marketcap) 20618213.16
時価総額 時価総額(百万ドル) 16.16258
売上高 売上高(百万ドル) 0.07200
企業価値(EV) 企業価値(EV)(百万ドル) 3.19458
当期純利益 当期純利益(百万ドル) -23.89900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Regulus Therapeutics Inc revenues remained flat at $36K. Net loss decreased 28% to $29.9M. Revenues reflect market conditions. Lower net loss reflects research decrease of 28% to $20.4M (expense) general decrease of 37% to $5.6M (expense) Stock-based Compensation in SGA decrease of 30% to $1.5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$9.41 to -$3.44.

 RGLSのテクニカル分析


 RGLSのニュース

   Mesmerizing stocks: Jupiter Wellness, Inc. (NASDAQ:JUPW -1.18%), Regulus Therapeutics Inc. (NASDAQ:RGLS 1.22%)  2021/10/09 12:34:18 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Mesmerizing stocks: Jupiter Wellness, Inc. (NASDAQ:JUPW -1.18%), Regulus Therapeutics Inc. (NASDAQ:RGLS 1.22%) appeared first on Stocks Equity .
   Rolling stocks: Flexion Therapeutics, Inc. (NASDAQ:FLXN -7.40%), Regulus Therapeutics Inc. (NASDAQ:RGLS -2.07%)  2021/09/26 23:26:47 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Rolling stocks: Flexion Therapeutics, Inc. (NASDAQ:FLXN -7.40%), Regulus Therapeutics Inc. (NASDAQ:RGLS -2.07%) appeared first on Stocks Equity .
   Honest Ways To pick this stocks: Aditxt, Inc. (NASDAQ:ADTX 3.13%), Regulus Therapeutics Inc. (NASDAQ:RGLS 1.35%)  2021/09/22 23:09:28 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Honest Ways To pick this stocks: Aditxt, Inc. (NASDAQ:ADTX 3.13%), Regulus Therapeutics Inc. (NASDAQ:RGLS 1.35%) appeared first on Stocks Equity .
   Weird But Effective stocks: Alset EHome International Inc. (NASDAQ:AEI 2.50%), Regulus Therapeutics Inc. (NASDAQ:RGLS -1.49%)  2021/09/15 21:57:31 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Weird But Effective stocks: Alset EHome International Inc. (NASDAQ:AEI 2.50%), Regulus Therapeutics Inc. (NASDAQ:RGLS -1.49%) appeared first on Stocks Equity .
   Key Benefits Of: Fangdd Network Group Ltd. (NASDAQ:DUO -8.63%), Regulus Therapeutics Inc. (NASDAQ:RGLS 1.25%)  2021/09/14 22:57:21 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Key Benefits Of: Fangdd Network Group Ltd. (NASDAQ:DUO -8.63%), Regulus Therapeutics Inc. (NASDAQ:RGLS 1.25%) appeared first on Stocks Equity .
   Rolling stocks: Flexion Therapeutics, Inc. (NASDAQ:FLXN -7.40%), Regulus Therapeutics Inc. (NASDAQ:RGLS -2.07%)  2021/09/26 23:26:47 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Rolling stocks: Flexion Therapeutics, Inc. (NASDAQ:FLXN -7.40%), Regulus Therapeutics Inc. (NASDAQ:RGLS -2.07%) appeared first on Stocks Equity .
   Honest Ways To pick this stocks: Aditxt, Inc. (NASDAQ:ADTX 3.13%), Regulus Therapeutics Inc. (NASDAQ:RGLS 1.35%)  2021/09/22 23:09:28 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Honest Ways To pick this stocks: Aditxt, Inc. (NASDAQ:ADTX 3.13%), Regulus Therapeutics Inc. (NASDAQ:RGLS 1.35%) appeared first on Stocks Equity .
   Weird But Effective stocks: Alset EHome International Inc. (NASDAQ:AEI 2.50%), Regulus Therapeutics Inc. (NASDAQ:RGLS -1.49%)  2021/09/15 21:57:31 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Weird But Effective stocks: Alset EHome International Inc. (NASDAQ:AEI 2.50%), Regulus Therapeutics Inc. (NASDAQ:RGLS -1.49%) appeared first on Stocks Equity .
   Key Benefits Of: Fangdd Network Group Ltd. (NASDAQ:DUO -8.63%), Regulus Therapeutics Inc. (NASDAQ:RGLS 1.25%)  2021/09/14 22:57:21 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Key Benefits Of: Fangdd Network Group Ltd. (NASDAQ:DUO -8.63%), Regulus Therapeutics Inc. (NASDAQ:RGLS 1.25%) appeared first on Stocks Equity .
   Griping stocks: Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX 1.82%), Regulus Therapeutics Inc. (NASDAQ:RGLS 2.47%)  2021/09/08 22:31:22 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Griping stocks: Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX 1.82%), Regulus Therapeutics Inc. (NASDAQ:RGLS 2.47%) appeared first on Stocks Equity .
   Regulus Therapeutics Inc. Consensus Indicates Potential -23.1% Downside  2021/06/23 12:03:27 DirectorsTalk
Regulus Therapeutics Inc. found using ticker (RGLS) now have 3 analysts covering the stock. The analyst consensus points to a rating of ''Hold''. The range between the high target price and low target price is between 1.5 and 0.5 calculating the mean target price we have 1. With the stocks previous close at 1.3 this now indicates there is a potential downside of -23.1%. The 50 day MA is 0.77 and the 200 moving average now moves to 0.69. The market cap for the company is $90m. You can visit the company''s website by visiting: /> [stock_market_widget type="chart" symbol="RGLS" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its two lead product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase Ib clinical trial for the treatment of autosomal dominant polycystic kidney disease.
   Stock Jumping on Abnormally High Volume: Regulus Therapeutics Inc. (NASDAQ:RGLS), Itau Unibanco Holding S.A. (NYSE:ITUB)  2021/06/14 22:19:38 Stock Equity
Regulus Therapeutics Inc. (NASDAQ:RGLS) with the stream of -3.85% also noticed, India Itau Unibanco Holding S.A. (NYSE:ITUB) encountered a rapid change of -0.24% in the last hour of Mondays trading The post Stock Jumping on Abnormally High Volume: Regulus Therapeutics Inc. (NASDAQ:RGLS), Itau Unibanco Holding S.A. (NYSE:ITUB) appeared first on Stocks Equity .
   What Historical Figures Say About This Stock? Regulus Therapeutics Inc. (NASDAQ:RGLS) encountered the change of -15.08%  2021/06/10 21:17:56 Stock Equity
On Thursday, Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) reached at $1.07 price level during last trade its distance from 20 days simple moving average was 5.88%, and its distance from The post What Historical Figures Say About This Stock? Regulus Therapeutics Inc. (NASDAQ:RGLS) encountered the change of -15.08% appeared first on Stocks Equity .
   Technical Indicators under Consideration: MICT, Inc. (NASDAQ:MICT), Regulus Therapeutics Inc. (NASDAQ:RGLS)  2021/06/09 21:40:17 Stock Equity
MICT, Inc. (NASDAQ:MICT) with the stream of -1.05% also noticed, India Regulus Therapeutics Inc. (NASDAQ:RGLS) encountered a rapid change of -0.82% in the last hour of trading session. MICT, Inc. The post Technical Indicators under Consideration: MICT, Inc. (NASDAQ:MICT), Regulus Therapeutics Inc. (NASDAQ:RGLS) appeared first on Stocks Equity .
   Regulus''s Polycystic Kidney Disease Candidate Shows Benefit At Interim Analysis  2021/05/21 14:47:46 Benzinga
Regulus Therapeutics Inc (NASDAQ: RGLS ) has announced an incremental update from the first cohort of patients from its ongoing Phase 1b trial evaluating RGLS4326 in Autosomal Dominant Polycystic Kidney Disease (ADPKD). ADPKD is a genetic disorder characterized by the growth of numerous cysts in the kidneys. In the first cohort, nine patients were enrolled Full story available on Benzinga.com

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 レグルス・セラピュ―ティクス RGLS Regulus Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)